Abstract Details
|
Christopher J. Yuskaitis, MD, PhD
(Takeda Pharacueticals)
PRESENTER |
Dr. Yuskaitis has nothing to disclose. |
| Maura R. Ruzhnikov, MD (Stanford University) | Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orchard Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Travere Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapetuics. The institution of Dr. Ruzhnikov has received research support from Grace Science Foundation. The institution of Dr. Ruzhnikov has received research support from Ionis Pharmaceuticals. The institution of Dr. Ruzhnikov has received research support from NIH. Dr. Ruzhnikov has a non-compensated relationship as a Co-founder and Secretary with Little Zebra Fund that is relevant to AAN interests or activities. |
| No disclosure on file | |
| Kevin O'Connor, FRACP, MB, BCh, BAO (Joondalup Health Campus) | No disclosure on file |
| Annapurna Poduri, MD | An immediate family member of Dr. Poduri has received personal compensation for serving as an employee of Beam Therapeutics. An immediate family member of Dr. Poduri has stock in Beam Therapeutics. The institution of Dr. Poduri has received research support from NIH. |
| Elliott H. Sherr, MD, PhD (UCSF) | No disclosure on file |